Chemist + Druggist is part of Informa PLC


This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

Teva unclear on which generics affected by Actavis buyout

Teva is unable to confirm how many generics it will take over from Actavis, following its $40.5 billion buyout of the UK manufacturing company.

Teva said its acquisition of Actavis Generics from owner Allergan yesterday (August 2) brings together "two leading generics businesses with complementary strengths".

When asked by C+D which of Actavis's more than 850 product lines would transfer over to its new owner, Teva said a full list will be published “in due course”.

As well as generics, "some" over-the-counter products are also being transferred to Teva, including Sudocrem and Infacol, it said.

"Too soon" for livery changes

It is “too soon” to anticipate any livery changes resulting from the takeover, Teva stressed.

“We are focusing our efforts on integrating the Actavis Generics business into Teva as smoothly as possible, with minimum disruption to our customers and patients,” a spokesperson told C+D.

In order for the deal to go ahead, the European Commission requires Teva to “guarantee continuity of competition” in the UK and Ireland by selling part of the Actavis business. As a result, Actavis's Barnstaple manufacturing plant and "a portfolio of generic molecules" will be sold in the "near future", Teva said.

"The remainder of Allergan's generics business in the UK and Ireland is to be integrated with Teva's," it added. 

What do you make of the deal?

Related Content

Topics



Pharmacist Managers - Recruiting Now !
East London, Essex and Luton
£40,000 - £50,000 per year

Apply Now
UsernamePublicRestriction

Register

CD008265

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel